I understand there've been some interest from those following SRX about other potential therapies, especially those working with the immune system. Three articles were reported this week in NEJM (http://www.nejm.org/) from ASCO showing significant improvements in PFS.
These are for Palbociclib, Elotuzumab and Nivolumab in breast, melenoma and squamous cell carcinoma respectively.
(For those unfamiliar, NEJM is the most prestigious generalist medical journal. )
In no way do these suggest the imminent demise of SRX, its a rich field with ample opportunities.
SRX Price at posting:
$30.16 Sentiment: Buy Disclosure: Held
